Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Opioid-free Anesthesia-Analgesia Strategy-University of Crete-non-small cell lung cancer
- Development stage
- Phase 4
- Lead developer
- University of Crete
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation, Oral, Local
01
Overview
The Opioid-free Anesthesia-Analgesia Strategy is a multimodal perioperative pharmacological protocol developed by the University of Crete for patients undergoing elective video-assisted thoracoscopic surgery (VATS) lobectomy for non-small cell lung cancer (NSCLC). This strategy aims to mitigate the immunosuppressive and hyperalgesic effects associated with exogenous opioids by utilizing a diverse combination of non-opioid agents. The protocol incorporates NMDA receptor antagonists (ketamine, magnesium sulphate), alpha-2 adrenergic agonists (dexmedetomidine, clonidine), local anesthetics (lidocaine, ropivacaine), gabapentinoids (pregabalin), and non-steroidal anti-inflammatory drugs (dexketoprofen), alongside standard anesthetic agents like propofol and desflurane. By targeting multiple pain and stress pathways, the strategy seeks to attenuate the surgical stress response and preserve immune function during major thoracic surgery.
- Other names
- OFA-AOpioid-Free Anaesthesia-Analgesia Strategy
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)ADRA2A (α2A)GABRR (GABA-A receptor subunit rho)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Opioid-free Anesthesia-Analgesia Strategy-University of Crete-non-small cell lung cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opioid-free Anesthesia-Analgesia Strategy-University of Crete-non-small cell lung cancer.